Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > Our Pipeline > Partnered Programmes Partnered Programmes Partnered Programmes In 2020 Crescendo entered into a clinical development partnership with Cancer Research UK for CB213, a novel bispecific PD-1 x LAG-3 antagonist. CB213 is a next-generation checkpoint inhibitor, which has been designed to deliver safer, more effective therapeutic intervention in patients with cancers resistant or refractory to PD-1 blockade alone. CB213 has demonstrated potent dual checkpoint blockade and the ability to enhance the activity of dysfunctional patient-derived T cells. A unique design enabling optimal dual target engagement. This molecule accesses novel biology not achievable with combinations of PD-1 and LAG-3 mAbs, with other alternative bispecific formats. ‘Dialled-down’ engagement of PD-1 to deliver an enhanced safety profile by avoiding the sink of peripheral PD-1 positive T-cells. CB213 only engages those highly exhausted, dysfunctional tumour-infiltrating lymphocytes (TILs) expressing both targets simultaneously. CB213 is small, robust Humabody® which benefits from extended circulatory half-life by use of a serum albumin-binding domain. Humabodies such as CB213 have optimal biodistribution characteristics, facilitating rapid tumour penetration and accumulation. Takeda has already licensed the first two (undisclosed) programmes in 2018 and 2019, under its global, strategic collaboration with Crescendo. Crescendo’s innovative, topical therapy CB001, (ZL-1102), for inflammatory indications including psoriasis, was licensed to Zai Lab in 2018. This programme is currently under evaluation in a phase 1 clinical trial (Trial ID: ACTRN12620000700932). Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design